Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
US Department of Justice
Merck
UBS
Federal Trade Commission
Moodys
Harvard Business School
Argus Health

Generated: September 20, 2018

DrugPatentWatch Database Preview

Sanofi Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI, and what generic alternatives to SANOFI drugs are available?

SANOFI has one hundred and fifty approved drugs.

There are seventy-three US patents protecting SANOFI drugs.

Drugs and US Patents for Sanofi

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us DEMI-REGROTON chlorthalidone; reserpine TABLET;ORAL 015103-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us PRESAMINE imipramine hydrochloride TABLET;ORAL 011836-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us TILADE nedocromil sodium SOLUTION;INHALATION 020750-001 Oct 1, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Sanofi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us CEPHULAC lactulose SOLUTION;ORAL, RECTAL 017657-001 Approved Prior to Jan 1, 1982 3,558,774 ➤ Try a Free Trial
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride SUSPENSION;ORAL 201373-001 Jan 24, 2011 6,399,632*PED ➤ Try a Free Trial
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007 5,496,545 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SANOFI drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 5 mg/mL, 10 mL and 20 mL vials ➤ Subscribe 2007-02-09
➤ Subscribe Injection 200 mg/40 mL ➤ Subscribe 2007-07-16
➤ Subscribe Extended-release Tablets 6.25 mg ➤ Subscribe 2006-02-24
➤ Subscribe Tablets 7 mg and 14 mg ➤ Subscribe 2016-09-12
➤ Subscribe Injection 2 mcg/mL, 2 mL ampules ➤ Subscribe 2007-10-15
➤ Subscribe Tablets 300 mg/25 mg ➤ Subscribe 2006-06-06
➤ Subscribe Injection 2 mcg/mL, 1 mL in 2 mL vial ➤ Subscribe 2011-12-28
➤ Subscribe Tablets 400 mg ➤ Subscribe 2013-07-01
➤ Subscribe Powder for Oral Suspension 0.8 g/packet and 2.4 g/packet ➤ Subscribe 2009-12-30
➤ Subscribe Tablets 150 mg ➤ Subscribe 2007-10-30
➤ Subscribe Transdermal System 7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs ➤ Subscribe 2014-05-30
➤ Subscribe Tablets 5 mg ➤ Subscribe 2007-12-17
➤ Subscribe Injection 100 mg/mL, 3 mL vials ➤ Subscribe 2006-12-07
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2007-02-09
➤ Subscribe Injection 5 mg/mL, 40 mL vial ➤ Subscribe 2011-03-23
➤ Subscribe Extended-release Tablets 12.5 mg ➤ Subscribe 2006-01-19
➤ Subscribe Capsules 0.5 mcg and 2.5 mcg ➤ Subscribe 2009-03-25
➤ Subscribe Tablets 150 mg/12.5 mg and 300 mg/12.5 mg ➤ Subscribe 2004-11-10
➤ Subscribe Capsules 1 mcg ➤ Subscribe 2010-02-12
➤ Subscribe Tablets 75 mg, 150 mg and 300 mg ➤ Subscribe 2004-05-25
➤ Subscribe Tablets 800 mg ➤ Subscribe 2008-12-04
➤ Subscribe Tablets 300 mg ➤ Subscribe 2009-03-04
➤ Subscribe Oral Suspension 30 mg/5 mL ➤ Subscribe 2010-01-25
➤ Subscribe Oral Solution 0.5 mg/mL ➤ Subscribe 2009-01-14
➤ Subscribe Injection 40 mg/mL, 0.5 mL and 2 mL vials ➤ Subscribe 2009-06-30
Premature patent expirations for SANOFI

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for Sanofi

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,147,870 Osmotic device containing pseudoephedrine and an H1 antagonist ➤ Try a Free Trial
6,528,486 Peptide agonists of GLP-1 activity ➤ Try a Free Trial
6,569,898 United States Patent: 6569898   ( 1 ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Sanofi Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0596 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
0883 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REGISTRATION NO/DATE: EU/1/16/1157 20170113
00021 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chubb
Cerilliant
US Department of Justice
Daiichi Sankyo
Healthtrust
US Army
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.